阿立哌唑与利培酮口服液治疗门诊老年期痴呆精神行为症状的对照研究

Control study of aripiprazole vs. risperidone oral solution in the treatment of behavioral and psychological symptoms of dementia in senile dementia outpatients

目的探讨阿立哌唑和利培酮口服液治疗门诊老年期痴呆精神行为症状(BPSD)的疗效和安全性。方法将68例老年期痴呆伴BPSD患者随机分成阿立哌唑组35例,利培酮口服液组33例,疗程8周,采用痴呆病理行为评定量表(BEHAVE-AD)及激越性问卷(CMAI)评定疗效,采用治疗中需处理的不良反应症状量表(TESS)评定副反应。结果两组治疗后第6、8周末BEHAVE-AD和CMAI评分与治疗前比较均显著下降(P<0.01),两组之间比较治疗前及治疗后各时间点比较BEHAVE-AD评分差异无统计学意义(P>0.05)。两组不良反应比较,阿立哌唑组不良发生率明显低于利培酮口服液组,差异有统计学意义(P<0.01)。结论阿立哌唑和利培酮口服液治疗老年期痴呆伴发BPSD均有较好疗效,两者总体疗效、起效时间相当,而阿立哌唑的安全性优于利培酮口服液。

Objective To study the efficacy and safety of aripiprazole vs. risperidone oral solution in the treatment of behavioral and psychological symptoms of dementia （BPSD） in senile dementia outpatients. Methods 68 senile dementia outpatients with BPSD were randomly divided into aripiprazole group （35 cases） and risperidone group （33 cases） treated with aripiprazole and risperidone oral solution respectively for 8 weeks. Efficiency were evaluated by using Behavioral Pathology in Alzheimer~ Disease Scale （BEHAVE-AD） and Cohen-Mansfield Agitation Inventory （CMAI） , and the side effects were evaluated by using Treatment Emergent Symptom Scale （TESS）. Results Compared with the baseline, scores of BEHAVE-AD and CMAI in both groups decreased significantly after the treatment in the 6＇h and 8＇h week （ P 〈 0.01 ）. There was no significant difference in decreased score of BEHAVE-AD between the two groups before the treatmeant and after the treatment in each point （P 〉 0.05 ）. The incidence of adverse reactions in aripiprazole group was significantly lower than that in risperidone group （P 〈 0.01 ）. Conclusion Aripiprazole and fisperidone oral solution both have good efficiency in the treatment of BPSD. Their overall efficiency and response time are similar, but aripiprazole has better safety.